ZYDEN GENTEC LIMITED
ANNUAL REPORT 2005-2006
CHAIRMAN`S REPORT
CHAIRMAN`S STATEMENT
Dear Members,
It is my privilege to provide the leadership to your company for more than
a decade. The vision of positioning the company as one of the valuable
corporations of India has been the inspirational force throughout, while
handling the reins of the company. We have successfully transformed the
difficult strategic choice of creating drivers of growth by matching proven
internal capabilities with emerging market opportunities. It is a matter of
pride and deep satisfaction for the team that during this period we have
not only grown the company to a significant size, but also created enormous
shareholder value.
As we progress into 2006, we see a world of new opportunities. The global
pharmaceutical industry is undergoing dynamic changes in the business
environment. On one hand, the developed markets led by the US are being
subjected to severe price erosion, while on other hand, emerging markets
have witnessed further increase in generic penetration, providing newer
opportunities to companies such as ours. The industry experienced
consolidation amongst its players, a trend that is expected to gain
momentum in the future. While our journey to become a discovery-led
pharmaceutical player continues unabated, we also have performed well
during the year. As a part of consolidation process and as the company
keeps growing, various options are being explored on acquisitions. The
company has also been in process of furthering business tie-ups with
various players of repute. The performance of the company during 2005-06
was in line with the business plans and the long term objectives.
Aim
Zyden offers its core competence in the field of new drug lead discovery.
Amino acid sequencing to understand receptor drug interactions and creating
logical ideas to modify Drug disease inter-relationship by modifying &
extending the HLB concept in diseases like Cerebral Malaria, Arthritis,
AIDS & Cancer.
Planning Strategies
Retrosynthesis and Creativity. Complex Organic Molecules and ingenious
synthetic solutions both in the field of Regio and Stereo synthesis. This
can be well assessed in the synthesis of Estrone or a multi-step synthesis
of Camptothecin Nucleus in Analog. Manipulations of are centered around the
creation of an Alkaloidal Skeleton with both Hydrophilic as well as
Lipohilic centres.
Operational Area
Application and Applied Research in the field of Anti-Diabetic Type II
Drugs and potential leads in Psoriasis. This work also includes Analytical
Profiling, Bio-transformation and deduction of potential impurities in
molecules which have pharmacologically interesting activities.
Pipeline of Actives
Since every chemical has a potential usage, a rapid methodology of
synthesis has been undertaken to synthesize compounds which have
applications. Lot of thinking goes in creating Analogs and series where
attempts are made to create long or short Carbon Chains, replace Amides
with Thioamides, protect Ketone to create Ketals and introduce carrier
groups. Zyden offers the inter-phase to provide better solutions to older
cumbersome chemistry. This inter-phase also gives chance to biologists to
use immense number of diverse compounds for their profiling, resulting in
faster solutions.
Successful growth will create risks and the risk management brings with it
optimism. However, there are many challenges ahead. There is a challenge of
successful integration; of being a global company; of creating managerial
pool; of dealing with increasing competitive pressures; of systematically
making successful launches across the entire product space; of further
strengthening the R&D; and of maintaining the momentum of rapid
transformation to become a globally recognized, discovery- led
pharmaceutical player.
With the various initiatives underway and the new product launches planned
for 2006-07, the company would be able to record an even better and
improved performance in 2006-07, capitalizing on the over-all, newly
emerging off-patent opportunities. I sincerely thank all for continuing to
repose confidence in the company as well as in the operating management.
Collectively, we will certainly maintain your trust and confidence.
Yours sincerely,
Sd/-
Date : 25th August, 2006 Vinod S Gupta
Place : Kota Chairman |